Applied Genetic Technologies Corp. (NASDAQ:AGTC) has received a consensus recommendation of “Hold” from the ten analysts that are covering the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $17.75.

AGTC has been the topic of several recent research reports. Zacks Investment Research raised Applied Genetic Technologies Corp. from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a report on Monday, October 17th. Wedbush reaffirmed an “outperform” rating and set a $17.00 target price (down from $20.00) on shares of Applied Genetic Technologies Corp. in a report on Wednesday. BMO Capital Markets cut their target price on Applied Genetic Technologies Corp. from $25.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, September 13th. Janney Montgomery Scott raised Applied Genetic Technologies Corp. from a “sell” rating to a “neutral” rating and set a $11.00 target price on the stock in a report on Monday, September 26th. Finally, Roth Capital reaffirmed a “neutral” rating and set a $12.00 target price on shares of Applied Genetic Technologies Corp. in a report on Sunday, October 23rd.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 9.85 on Wednesday. The stock’s 50 day moving average price is $8.58 and its 200 day moving average price is $13.00. Applied Genetic Technologies Corp. has a 52 week low of $6.35 and a 52 week high of $21.43. The firm’s market cap is $177.82 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last issued its quarterly earnings data on Tuesday, November 8th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.28. The business had revenue of $11.80 million for the quarter, compared to analyst estimates of $10.21 million. Applied Genetic Technologies Corp. had a return on equity of 10.56% and a net margin of 23.63%. Applied Genetic Technologies Corp.’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.53) EPS. On average, equities research analysts predict that Applied Genetic Technologies Corp. will post ($0.61) EPS for the current year.

In other news, insider Mark S. Shearman purchased 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The shares were acquired at an average cost of $8.87 per share, with a total value of $26,610.00. Following the purchase, the insider now owns 1,700 shares in the company, valued at $15,079. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Lawrence E. Bullock purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 19th. The shares were purchased at an average cost of $8.75 per share, for a total transaction of $87,500.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $87,500. The disclosure for this purchase can be found here. Corporate insiders own 2.46% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its position in Applied Genetic Technologies Corp. by 68.3% in the second quarter. Acadian Asset Management LLC now owns 498,825 shares of the company’s stock worth $7,047,000 after buying an additional 202,361 shares during the period. Adams Diversified Equity Fund Inc. bought a new stake in shares of Applied Genetic Technologies Corp. during the second quarter worth approximately $239,000. Bank of Montreal Can bought a new stake in shares of Applied Genetic Technologies Corp. during the second quarter worth approximately $565,000. Smith Asset Management Group LP raised its stake in shares of Applied Genetic Technologies Corp. by 292.5% in the second quarter. Smith Asset Management Group LP now owns 25,200 shares of the company’s stock worth $356,000 after buying an additional 18,780 shares in the last quarter. Finally, Strs Ohio raised its stake in shares of Applied Genetic Technologies Corp. by 3.7% in the second quarter. Strs Ohio now owns 42,300 shares of the company’s stock worth $597,000 after buying an additional 1,500 shares in the last quarter. 61.31% of the stock is currently owned by institutional investors and hedge funds.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

5 Day Chart for NASDAQ:AGTC

Receive News & Stock Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related stocks with our FREE daily email newsletter.